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RESEARCH ARTICLE
Folate receptor-targeted mixed polysialic acid micelles for combating
rheumatoid arthritis: in vitro and in vivo evaluation
Nan Zhanga,b,c, Chunyu Xud, Na Lia, Shasha Zhanga, Lingling Fua, Xiao Chua, Haiying Huad, Xianghui Zenge and
Yongxing Zhaoa,b,c
aDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan, PR China; bKey Laboratory of
Targeting Therapy and Diagnosis for Critical Diseases, HeNan Province, Zhengzhou, HeNan, PR China; cKey Laboratory of Advanced
Pharmaceutical Technology, Ministry of Education of China, HeNan Province, Zhengzhou, HeNan, PR China; dInstitute of Medical and
Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, HeNan, PR China; eDepartment of Pharmacy, University of Copenhagen,
Copenhagen, Denmark
ABSTRACT
Objective: Rheumatoid arthritis (RA) is associated with chronic inflammation. The suppression of
inflammation is key to the treatment of RA. Glucocorticoids (GCs) are classical anti-inflammatory drugs
with several disadvantages such as poor water solubility and low specificity in the body. These disad-
vantages are the reasons for the quick elimination and side effects of GCs in vivo. Micelles are ideal
carriers for GCs delivery to inflamed synovium. We set out to improve the targeting and pharmacoki-
netic profiles of GCs by preparing a targeting micelle system.
Methods: In this study, natural chlosterol (CC) and folic acid (FA) were used to fabricate polysialic acid
(PSA) micelles for the targeted delivery of Dexamethasone (Dex). The biodistribution and therapeutic
efficacy of the resulting micelles were evaluated in vitro and in vivo.
Results: PSA-CC and FA-PSA-CC micelles showed a size below 100nm and a moderate negative charge.
PSA-CC and FA-PSA-CC micelles could also enhance the intracellular uptake of Dex and the suppression
of tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) in vitro and in vivo. Arthritis mice showed
reduced paw thickness and clinical arthritis index using PSA-CC and FA-PSA-CC micelle treatment.
Micellized Dex demonstrated a 4 5 fold longer elimination half-life and a 2 3 folds higher bioavail-
ability than commercial Dex injection. FA modification significantly improved the anti-inflammatory
efficacy of PSA-CC micelles.
Conclusion: FA-PSA-CC micelles demonstrated significant advantages in terms of the suppression of
inflammation and the treatment of inflammatory arthritis. These reliable and stable micelles possess a
high potential to be transferred for clinical use.
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Rheumatoid arthritis (RA) is one of the most severe auto-
immune disordered diseases. RA has an incidence 1% world-
wide and severe RA causes cartilage damage, bone resorption,
organ injuries, and shortened life span. Despite modern med-
ical progress, the pathogenesis of RA is unclear and the clinical
diagnosis and treatment for RA stay in a semi-empirical phase.
One of the most significant features of autoimmune diseases
like RA is the activation of immune cells and immune
responses, leading to chronic inflammation. In inflamed syno-
vium, the co-stimulation of T cells and B cells activated macro-
phages to secrete various pro-inflammatory proteins such as
TNF-a, IL-1, etc. The activated macrophages and T cells also
stimulated synovial fibroblasts to express receptor activator for
nuclear factor-jB ligand (RANKL) and matrix metalloproteinases
(MMPs), which causes osteoclast activation, bone resorption,
and cartilage degradation (Bader & Wagoner, 2010; Wagoner &
Bader, 2012). Together, pro-inflammatory proteins and
the activation of intracellular inflammatory signaling pathways
result in the activation of multiple immune cells in inflamed
synovium, which leads to chronic inflammation and irreversible
tissue damage. The suppression of chronic inflammation is
one of the most important strategies for RA treatment.
Glucocorticoids (GCs) are cheap and efficient therapeutics
for anti-inflammatory use in clinical setting over centuries.
However, GCs like Dexamethasone (Dex) possess unspecific
distribution and fast elimination after administration to the
body. The lack of specificity to inflamed synovium leads to
repeated administration in order to achieve an effective drug
concentration, which usually causes various side effects to
health tissues and reduces patient compliance. Improvements
to the targeting and pharmacokinetic profiles of classical GCs
are highly needed and significant in clinical setting.
Micelles are ideal carriers for poorly water-soluble mole-
cules. Functional material have been used for the fabrication
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of micelles (Zhang et al., 2013) and various micelles have
been developed in academic articles. However, only a few of
these published micelles entered clinical studies so as to bene-
fit patients. Past experience indicated that micelles with good
safety, high efficacy, and easy synthesis and modification
possess a higher possibility to be transferred into clinical use.
PEGylation has been the most successful strategy to increase
the solubility and prolong circulation time in vivo. However,
PEG is hard to degrade, which may lead to the accumulation
of high molecule weight PEG in the body. Some polysacchar-
ides, like polysialic acid (PSA), (Drake et al., 2008) have similar
properties to PEG and are biodegradable and excretable.
Previously, PSA has been used for the development of micelles
(Bader et al., 2011; Wilson et al., 2014; Zhang et al., 2014). As
an alternative material to PEG, PSA is highly hydrophilic, bio-
compatible, and biodegradable. The FALT of PSA is similar to
that of PEG, which indicates that the water absorbing ability
of PSA is similar to that of PEG. PSA was firstly discovered on
the surface of pathogenic bacteria. The thick coating of PSA on
the cell wall facilitate bacteria to escape the host immune sys-
tem and evade the host tissues. Further studies showed an anti-
adhesive property of PSA (Elward & Gasque, 2003; Gregoriadis
et al., 2005). PSA-conjugated insulin, asparaginase, and catalase
have shown prolonged half-life in vivo (Fernandes & Gregoriadis,
1994, 1996, 1997, 2001; Jain et al., 2003; Gregoriadis et al.,
2005). These reported properties show the potential of PSA as a
stealth biomacromolecule for micelle development.
In this study, hydrophobic cholesteryl chloroformate (CC)
was conjugated to PSA to prepare micelles for Dex loading. To
enhance the targeting to inflamed synovium, folic acid (FA)
modified PSA-CC micelles were also developed by forming a
mixed micelle system. PSA-CC and FA-PSA-CC micelles were
characterized in terms of their physiochemical properties and
evaluated for their in vitro toxicity, anti-inflammatory efficacy,
and interaction with immune cells. Furthermore, these micelles
were monitored for their safety and examined for their in vivo
distribution, the efficacy on the treatment of adjuvant induce
arthritis (AIA) mice, and pharmacokinetics. Our study will demon-
strate the potential of the developed micelles for RA treatment.
Material and methods
Material, cell culture and animals
PSA was purchased from HuBei HengLuYuan Technology Co.,
Ltd (HuBei, China). Sigma supplied cholesteryl chloroformate,
tetrabutylammonium bromide, DOWEX 50WX2 ion-exchange
resin, IR-780 iodide, and Dex. 1,2-Distearoyl-sn-glycero-
3-phosphoethanolamine polyethylene glycol-folic acid (DSPE-
PEG-FA) was obtained from Nanocs (New York, NY). Pyrene
was purchased from Alfa Aesar (Ward Hill, MA).
Lipopolysaccharide (LPS) and Complete Freund’s adjuvant
were purchased from Sigma Corporation (Cram Ridge, NJ).
HyClone Laboratories Inc. (South Logan, UT) supplied penicil-
lin–streptomycin solution (100). Gibco (Carlsbad, CA) pro-
vided fetal bovine serum (FBS). 0.25% trypsin, DMEM culture
medium, DAPI solution were supplied by Solarbio (Beijing,
China). ELISA kit was purchased from MultiSciences
(LiankeBio) (Hangzhou, China). RAW 264.7 and Ges-1 cells
were purchased from CoBioer (Nanjing, China).
Synthesis of PSA-CC and FA-PSA-CC micelles
Synthesis of micelles were finished in DMSO/dichloromethane
co-solvent system (Yao et al., 2014). The sodium ion of PSA
was firstly exchanged to tetrabutylammonium to increase the
solubility of PSA in DMSO according to a reported procedure
(Wilson et al., 2014) (see details in Supplementary material).
To synthesize PSA-CC, 16mg of ion exchanged PSA (51.
2 lmol sialic acid monomer) was added into 2.5ml of anhyd-
rous DMSO. PSA was dissolved well using sonication. About
10 lL triethylamine (TEA) was subsequently mixed into the
DMSO solution. Simultaneously, 14mg CC (0.031mmol, 0.6
equiv. relative to sialic acid monomer) was dissolved in 1.5ml
of anhydrous dichloromethane. The dichloromethane solution
was added slowly to the DMSO solution with stirring in N2
atmosphere. The mixture was stirred for 48 h at room tem-
perature. Dichloromethane was removed by rotary evapor-
ation. PSA-CC solution was subsequently filtered and dialyzed
against 150mM NaCl solution for 3 days to remove solvent
residual and exchange tetrabutylammonium back to sodium.
Purified PSA-CC was obtained by lyophilization and analyzed
by FTIR and 1H-NMR. To prepare FA-PSA-CC, 2ml dichloro-
methane that contained 1.5mg DSPE-PEG-FA (MW5000) was
added to the evaporated PSA-CC solution. About 2ml DI
water was subsequently added under vigorous stirring. The
solution was rota-evaporated after 20min stirring and was
subsequently filtered and dialyzed against 150mM NaCl solu-
tion for 3 days. Purified FA-PSA-CC was obtained by lyophil-
ization and analyzed by FTIR and 1H-NMR (Scheme 1(A)).
Characterization of PSA-CC and FA-PSA-CC micelles
Critical micelle concentration
Critical micelle concentration (CMC) was evaluated via
steady-state ﬂuorescence using pyrene as a probe. Both
PSA-CC and FA-PSA-CC solution were diluted into 11 samples
(dilution from 1mg/mL to 0.98lg/mL). About 1mL of each
sample was mixed with 8.1lL of a 1.24 104 M acetone
solution of pyrene. The solutions were sonicated for 30min
at room temperature and heated at 65 C under shaking for
4 h to achieve equilibration. After cooling in the dark over-
night, excitation spectra were recorded at an emission wave-
length of 390 nm using a RF-5301PC (Shimadzu Corporation,
Kyoto, Japan) ﬂuorescence spectrophotometer.
Transmission electron microscopy
Lyophilized PSA-CC and FA-PSA-CC were dissolved in de-
ionized water (DI) water to prepare the 0.1mg/mL micelle sol-
utions of PSA-CC and FA-PSA-CC. About 20lL of the solutions
was pipetted onto a carbon-coated copper grid (Beijing
Xinxing Braim Technology Co., Ltd, Beijing, China). The excess
micelle solution was removed, and the sample was observed
under transmission electron microscopy (TEM; TecnaiG20; FEI,
Hillsboro, OR).
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Size and zeta potential
Size, polydispersity (PDI), and zeta potential of PSA-CC and
FA-PSA-CC micelles were obtained using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK). Aqueous samples were
prepared by dissolving 10mg PSA-CC and FA-PSA-CC in 1ml
DI water and tested at 25 C, respectively.
Dex loading and release
One milligram of PSA-CC or FA-PSA-CC and 0.1–0.4mg of
Dex were added to acetonitrile and stirring for 1 h. The mix-
ture was subsequently rota-evaporated at 65 C to remove
acetonitrile and formed a film at the bottom of flask.
Scheme 1. (A) Synthesis of PSA-CC micelles. (B) Illustration of the compositions of PSA-CC/Dex micelles and FA-PSA-CC/Dex micelles.
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Two milliliter of DI water was refilled to the flask. The flask
was sonicated for 5min and filtered through 0.8lm mem-
brane. Loading capacity (LC) and loading efficiency (LE) were
analyzed by high-performance liquid chromatography (HPLC)
(Agilent 1100, Beijing, China) (column: Diamonsil C18, 5 lm,
200 4.6mm; mobile phase: methanol/water 7/3; flow rate:
1mL/min1; UV detection wavelength: 240 nm; temperature:
25 C; injected samples: 20 lL). About 250 lL of Dex-loaded
micelles were mixed with 250 lL methanol and the samples
were injected for HPLC analysis. Dex-loaded PSA-CC and
FA-PSA-CC were also characterized for size, zeta potential,
thermal stability and Dex release. Size and zeta potential were
conducted as above. For thermal stability test, 1mL of Dex-
loaded micelles was incubated for 6 days at 37 C with daily
measurement of micelle size and PDI. Dex release was con-
ducted in dialysis tubes. Briefly, 5mL of Dex-loaded micelles
was transferred into a dialysis tube (molecular weight cut off
[MWCO] 12K–14K). The tube was submerged into 45mL DI
water (37 C, pH 7.4). At set time points (10min, 20min,
40min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h and 72 h), 1mL sink
solution was taken as a sample and 1mL fresh DI water was
refilled. The samples were analyzed as above using HPLC.
Cellular uptake of coumarin-loaded micelles by
macrophages
To test intracellular delivery of molecules by micelles devel-
oped in this study, lipophilic coumarin that shows green fluor-
escence was loaded to PSA-CC and FA-PSA-CC micelles.
Cellular internalization of coumarin was studied using A1 laser
confocal microscopy (Nikon, Japan) on RAW 264.7 cells. Briefly,
RAW 264.7 cells were seeded in 24 well plates with a cell dens-
ity of 7.5 104 cells per well. The cells were stimulated by LPS
for 24 h. Coumarin solution, coumarin-loaded PSA-CC, and
coumarin-loaded FA-PSA-CC were added to the wells and cul-
tured for 0.5, 1, 2, and 4 h. Medium in each well was removed
and cells were washed thrice with PBS after incubation. About
2mL 4% paraformaldehyde was then added to each well. The
cells were incubated for 10min in the dark. Subsequently, the
cells were washed with PBS thrice and 400 lL DAPI solution
was used to stain cells for 5min. The cells were washed thrice
using PBS and observed under microscope.
To quantify the cellular uptake, coumarin, coumarin-
loaded PSA-CC, and coumarin-loaded FA-PSA-CC were added
to RAW 264.7 cells (a cell density of 3 105 cells per well)
and cultured for 4 h, respectively. Subsequently, cells were
washed thrice using cold PBS. Five hundred microliter trypsin
was added to each well and the detached cells were washed
twice with PBS. Subsequently, the cells were centrifuged at
1000 r/min for 5min. Cell pellet was washed and suspended
with PBS for twice and analyzed using a BD FACS Canto II
flow cytometer (BD Biosciences, Oxford, UK).
In vitro anti-inflammatory efficacy in activated
macrophages
RAW 264.7 cells in exponential phase of growth were seeded
to 96-well plates at a cell density of 1.5 104 cells per well.
The cells were stimulated by 1 lg/ml LPS for 24 h to establish
inflammatory cell models. Controls, Dex (0.1mg/mL, 1mg/mL),
Dex (0.1mg/mL) loaded PSA-CC, and Dex (0.1mg/mL)
loaded FA-PSA-CC were added to the inflammatory cells
and incubated for 24 h. Cell supernatant was collected and
tested by ELISA kit to determine the concentration of TNF-a
and IL-6.
In vivo anti-inflammatory efficacy in AIA mice
Biodistribution
IR-780 is a lipophilic and fluorescent molecule with good
stability in vivo. IR-780 was loaded to PSA-CC and FA-PSA-CC
micelles using the same method to Dex. AIA mice were ran-
domly divided into three groups for the injection of IR-780
solution (0.2mg IR-780 per mg mice, 100 lL), IR-780 (0.2mg
IR-780 per mg mice, 100lL) loaded PSA-CC, and IR-780
(0.2mg IR-780 per mg mice, 100 lL) loaded FA-PSA-CC. At 2,
6, 16, and 24 h after tail veil injection, the mice were anesthe-
tized and observed for dynamic fluorescent distribution in
mice using In Vivo Imaging System FX PRO (excitation wave-
length 770 nm, emission wavelength 840 nm, X-ray exposure
time 30 s) (Bruker; Billerica, MA).
Efficacy study
SPF Swiss male mice (body weight around 23–27g) were pur-
chased from the Experimental Animal Center of Zhengzhou
University. Animal care and experiments were performed with
the approval of the animal ethical committee of Zhengzhou
University (Zhengzhou, China), according to the requirements
of the National Act on the Use of Experimental Animals
(China). All animals were kept in a favorable environment and
were acclimated at 25 C and 55% of humidity under natural
light/dark conditions, with free access to a rodent diet and
water. The experimental animals were acclimated for 1 week
before the beginning of the study. Experimental mice were
injected with 40lL Freund’s adjuvant (10mg/mL). Mice with
inflamed paw were selected after 15 days and randomly
divided into five groups for the injection of 200lL saline every
other day to normal mice, 200lL saline every other day to
inflamed mice, Dex solution (0.02mg Dex per mouse every
other day), Dex-loaded PSA-CC solution (0.02mg Dex per
mouse every other day), and Dex-loaded FA-PSA-CC solution
(0.02mg Dex per mouse every other day). The treatment
lasted for 10 days. Paw thickness, paw inflammation, and paw
flexibility were recorded every other day. Arthritis clinical index
of mouse joints was calculated based on the paw thickness,
paw inflammation, and paw flexibility. The mice were sacrificed
after treatment (at Day 10) and 0.5mL of blood samples were
collected. ELISA kit was used to determine the concentration of
TNF-a and IL-6 in blood. The joints of mice were collected and
sliced for histological examination. The histological slices were
dyed with HE and examined by a Leica DM3000 light micro-
scope (Leica Microsystems, CMS GmbH, Wetzlar, Germany).
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Pharmacokinetics study in AIA rats
The pharmacokinetic (PK) study was conducted on Sprague-
Dawley rats. The rats weighting 200 ± 20 g were injected with
100lL Freund’s adjuvant (10mg/mL) subcutaneously at the
base of rat tail. Rats with inflamed paw were selected after
15 days and were divided into three groups for the injection of
Dex solution (0.05mg Dex in 0.5mL per rat), Dex-loaded PSA-
CC solution (0.05mg Dex in 0.5mL per rat), and Dex-loaded
FA-PSA-CC solution (0.05mg Dex in 0.5mL per rat). Blood sam-
ples (0.3mL) were collected into heparinized Eppendorf tubes
at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, and 48 h after tail vein
administration. Blood plasma was obtained by centrifuging at
4000 rpm for 10min. Subsequently, the plasma (0.1mL) was
mixed with 0.1mL methanol, shaken by a vortex mixer for
3min, and centrifuged at 3500 rpm for 15min. The super-
natant was determined by HPLC (as described above) for Dex
concentration. Pharmacokinetics parameters were calculated
by PK-Solver software (Redmond, WA).
Safety of micelles in AIA mice
On Day 24 after induction, the levels of aspartate aminotrans-
ferase (AST) and alanine transaminase (ALT) in blood were
determined in AIA mice treated by Dex solution, Dex-loaded
PSA-CC, and Dex-loaded FA-PSA-CC. These levels were meas-
ured using an automatic biochemical analyzer. At the same
time, white blood cell counts and lymphocyte counts were
determined using a standard hematology method.
Results
Synthesis and characterization of PSA-CC and FA-PSA-CC
micelles
FTIR spectrums indicated hydroxyl and amide functional
group and of PSA around 3400 and 1650 cm1, respectively.
CC showed featured acyl chloride peak at 1790 cm1,
carbon–hydrogen bond at 2950 cm1, and double peaks for
C(CH3)2 at 1400 cm
1. Successful conjugation of CC to PSA
destroyed acyl chloride group and resulted in the peak dis-
appearance at 1790 cm1. (Figure 1(A)) NMR result of PSA-CC
also confirmed the appearance of hydrogens that belonged
to CC at 0.5–1.5 ppm. (Supplementary Figure S1) CMC results
indicated that PSA-CC and FA-PSA-CC started to form
micelles at the concentration of 46.2 ± 3.9 and 32.1 ± 5.
2 lg/mL, respectively (Supplementary Figure S2(A,B)). TEM
showed a round shape of PSA-CC and FA-PSA-CC micelles with
the size 80–100nm (Figure 1(B,C)). TEM results were consistent
with dynamic light scattering results. The size of PSA-CC and
FA-PSA-CC micelles was 93.8±13.4 and 83.8±13.4nm respect-
ively using zeta-sizer. Both of PSA-CC and FA-PSA-CC micelles
showed a sufficient negative charge and small PDI, indicating
a high stability in solution (Supplementary Figure S2(C)). With
Dex loading, the size of PSA-CC and FA-PSA-CC micelles
increased slightly (Supplementary Figure S3).
Dex loading and release, and micelle stability
LC and LE of Dex to micelles were optimized by loading var-
ied amount of Dex. Results showed that a highest LC of Dex
to PSA-CC and FA-PSA-CC micelles was obtained when the
ratio of Dex to micelles is 0.3–1.0mg. At this ratio, 0.1mg
of Dex was encapsulated by 1mg micelle and 33.3% of ini-
tially added Dex was loaded into micelles (Figure 1(D,E)).
Slight size and PDI increase of FA-PSA-CC/Dex micelles was
observed during the 6-day incubation at 37 C (Figure 1(F)).
Figure 1(G) showed the release profile of Dex from PSA-CC
and FA-PSA-CC micelles. Around half of loaded Dex was
released at 6 h and 70–80% loaded Dex was released at 72 h.
In vitro study
The cytotoxicity of PSA-CC and FA-PSA-CC micelles was tested
in RAW 264.7 and GES-1 cells. IC50 values of PSA-CC micelles to
Figure 1. Characterization of the micelles. (A) FTIR spectrum of micelles and compositions for the blank micelles. (B) TEM image of PSA-CC micelles. (C) TEM image
of FA-PSA-CC micelles. (D) Loading capacity and loading efficiency of PSA-CC/Dex micelles. (E) Loading capacity and loading efficiency of FA-PSA-CC/Dex micelles.
(F) Particle size and PDI of FA-PSA-CC/Dex micelles. (G) Dex release from PSA-CC micelles and FA-PSA-CC micelles.
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RAW 264.7 and GES-1 cells were 4.98±0.73 and 9.97±0.98mg/
mL, respectively; IC50 values of FA-PSA-CC micelles to RAW
264.7 and GES-1 cells were 5.85±0.58 and 11.69±0.48mg/mL,
respectively. Micelles (1mg/mL) showed insignificant cytotox-
icity to RAW 264.7 and GES-1 cells and thus were considered
to be safe for in vitro study (Figure 2(A,B)). Dex, Dex-loaded
PSA-CC and FA-PSA-CC micelles were assayed for their anti-
inflammatory responses. PSA-CC and FA-PSA-CC did not induce
the expression of TNF-a and IL-6 (Supplementary Figure S4).
All treatment could reduce the production of TNF-a and IL-6.
Dex-loaded FA-PSA-CC (0.1mg/mL of Dex) resulted in a higher
reduction of TNF-a and IL-6 than Dex (0.1mg/mL) and Dex-
loaded PSA-CC (0.1mg/mL of Dex). FA-PSA-CC could increase
the anti-inflammatory efficacy of Dex (Figure 2(C,D)). FA-PSA-
CC group showed the strongest fluorescence in cells, indicating
that FA-PSA-CC micelles possessed the most intracellular
delivery of coumarin (Supplementary Figure S4) Further intern-
alization studies showed the most coumarin accumulation in
cytoplasm (Supplementary Figure S5). Analysis using flow
cytometer confirmed that the ratio of coumarin delivered by
PSA-CC to free coumarin is 1.81, and the ratio of coumarin
delivered by FA-PSA-CC to free coumarin is 4.35 (Figure 3).
In vivo study
Inflammatory mice were treated every other day for 10 days.
Paw thickness and other inflammatory parameters were
measured every other day. Clinical arthritis scores were calcu-
lated based on the sum of paw thickness, paw inflammation,
and paw flexibility. Figure 4(A,B) showed that Dex and Dex-
loaded PSA-CC and FA-PSA-CC micelles caused a significant
decrease of paw thickness and clinical arthritis scores.
Dex-loaded FA-PSA-CC micelles showed the highest reduc-
tion of paw thickness and clinical arthritis scores. Blood sam-
ples were obtained and tested after the 10 days’ treatment.
The serum concentration of TNF-a and IL-6 in mice that were
treated by Dex-loaded PSA-CC and FA-PSA-CC micelles was
significantly reduced compared to mice treated by Dex solu-
tion (Figure 4(C,D)). Pathological slides showed that normal
mice and mice treated with Dex-loaded PSA-CC and FA-PSA-
CC micelles possessed smooth cartilages and no pannus inva-
sion, whereas untreated mice showed cartilage and bone
damage. Mice treated by Dex demonstrated an abnormal
structure of joint (Figure 4(E)).
The number of white blood cells in mice treated with Dex,
PSA-CC/DexM and FA-PSA-CC/DexM is similar to that in nor-
mal mice. The number of lymphocytes in mice treated with
Dex, PSA-CC/DexM and FA-PSA-CC/DexM is less than that in
normal mice. However, FA-PSA-CC/DexM reduced the decrease
of lymphocytes caused by Dex and the number of lympho-
cytes in FA-PSA-CC/DexM treated mice was closer to that in
normal mice (Figure 4(F,G)). AST and ALT are indicative param-
eters for liver function. Mice treated by Dex-loaded micelles
showed similar level of AST and ALT to that in normal mice,
whereas free Dex treatment caused an increase of AST and
ALT in plasma. The results indicated that a high biocompatibil-
ity of the developed micelles (Figure 4(H)).
The biodistribution of PSA-CC and FA-PSA-CC micelles was
studied in AIA mice. The results showed that fluorescence was
not observed in mice injected with free IR-780, whereas strong
Figure 2. Inhibition rate of PSA-CC micelles and FA-PSA-CC micelles on RAW 264.7 cells (A) and GES-1 cells. (B) Concentration of TNF-a (C) and IL-6 (D) in RAW
264.7 cells with listed treatment.
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fluorescence was shown in the paw of mice that were injected
with IR780-loaded PSA-CC micelles (PSA-CC/IR780M) and
FA-PSA-CC micelles (FA-PSA-CC/IR780M). Mice treated with
FA-PSA-CC/IR780M generally demonstrated stronger fluores-
cence than that treated by PSA-CC/IR780M (Figure 5(A)). The
pharmacokinetics (PK) of Dex-loaded micelles was also
explored. After injection, blood samples were collected at set
time points for the study of PK in AIA rats. At 12h, Dex was
barely detected in the blood of rats that were injected with
free Dex, whereas the blood concentration of Dex was still
detectable at 48h in rats that were injected with Dex-loaded
micelles. PK parameters were calculated using the blood
concentration of Dex. Results showed that PSA-CC and FA-
PSA-CC micelles have significantly increased the t1/2b, AUC,
and MRT of Dex in AIA rats (Figure 5(B,C)).
Discussion
Many effective anti-rheumatic drugs are small hydrophobic
molecules, such as methotrexate, Dex, and cyclosporine A.
However, their use is gradually replaced by new and expen-
sive therapies such as TNF-a inhibitors and IL-1 inhibitors
because the poor in vivo PK/PD and high risk of side effects
of the traditional drugs. In this study, we aim to improve the
Figure 3. Cellular uptake of PSA-CC micelles and FA-PSA-CC micelles. (A) Fluorescent images of coumarin and coumarin-loaded micelle treated macrophages.
(B) Flow cytometric graphs of fluorescent intensity of coumarin in macrophages that treated as listed.
Figure 4. Paw thickness (A) and clinical index (B) of mice with listed treatment. Concentration of serum TNF-a (C) and IL-6 (D) in AIA mice with listed treatment.
(E) Images of histological slides from AIA mice with listed treatment. Safety evaluation: the concentration of (F) White blood cell, (G) lymphocyte, (H) AST, and ALT
in blood with listed treatment.
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use of traditional drugs via drug delivery technology. Quan
et al. (2014) have previously conducted a comparison study
of Dex-containing polymers, micelles, and liposomes for
inflammatory arthritis treatment (Quan et al., 2014). The
results showed that Dex-loaded micelles are one of the best
treatments in protecting the bone and reducing joint
swelling, disease activity, and histology score of the joints.
Compared to liposomes, micelles with low CMC possess
reduced pre-leakage of small hydrophobic drug molecules.
Micelles are more advantageous than dendrimers and poly-
meric conjugates because the loading of GC to micelles does
not need chemical reaction. For small hydrophobic drug mol-
ecules, micelles provide a higher drug loading capacity and
better protection than polymeric nanoparticles. Therefore,
micelles are chosen in this study to improve Dex delivery.
Compared to other reported micelles, our micelles use PSA
to replace PEG for prolonged circulation in vivo, and the
amphiphilic FA is used to increase the stability, loading cap-
acity, and active targeting of our mixed micelles. Such self-
assembled mixed micelles are more easily to be prepared
than other advanced micelles that need further synthesis.
What’s more important, this is the first study to demonstrate
the advantages of PSA-based micelles for Dex delivery in
vitro and in vivo.
PEG has been the gold standard to increase the in vivo cir-
culation of therapeutics. However, PEG is undegradable in
vivo. Long term use of PEG may cause toxicity and immune
responses (Semple et al., 2005; Webster et al., 2007; Hamad
Figure 5. (A) Biodistribution of IR780, PSA-CC/IR780 micelles, and FA-PSA-CC/IR780 micelles in AIA mice. (B) Concentration of serum Dex in AIA mice with listed
treatment. (C) Key pharmacokinetics parameters of Dex, PSA-CC/Dex micelles, and FA-PSA-CC/Dex micelles in AIA mice.
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et al., 2008). Biodegradable macromolecules that have similar
properties to PEG are potential alternatives to PEG for the
next generation of nanomedicines (Bader & Wardwell,
2014). Inspired by the natural stealth property of PSA, PSA-
based drug delivery systems have been developed to reduce
the in vivo clearance and prolong the in vivo circulation
of drugs. Gregoriadis (2005) is a pioneer for the studies of
sialylated and polysialylated therapeutics (Fernandes &
Gregoriadis, 1994, 1996, 1997, 2001; Jain et al., 2003) and
have founded Xenetic Biosciences, Inc. (Lexington, MA) in
1997 based on these technologies (PolyXenTM). PolyXenTM
has been a clinically proved platform technology to improve
the circulation and other pharmacological properties of pro-
tein or peptide therapeutics. Although sialylated and polysia-
lylated therapeutics demonstrated better efficacy, sialic acid
or PSA-drug conjugates are limited by their small size (quick
clearance) and low drug loading compared to micelles, nano-
particles, and liposomes. Our group have previously devel-
oped PSA-based micelles for the treatment of rheumatoid
arthritis (Bader et al., 2011). PSA-decylamine (DA) micelle
failed because of its high cytotoxicity. PSA-polycaprolactone
(PCL) micelles are biocompatible but need multi-step chem-
ical synthesis. A biocompatible micelle system that can be
synthesized via one step and controlled precisely for its com-
positions is highly needed.
Cholesterol (CC), a natural and essential molecule for the
body, was selected as the hydrophobic moiety of our micelles.
CC was conjugated to PSA via one-step reaction. Amphiphilic
DSPE-PEG-FA was mixed with PSA-CC to develop the targeted
FA-PSA-CC micelles (Scheme 1(B)). PSA-CC and FA-PSA-CC
formed micelles at a lower concentration than PSA-DA micelles
and PSA-PCL micelles, indicating that PSA-CC and FA-PSA-CC
micelles possessed a better physiochemical stability. PSA-CC
and FA-PSA-CC micelles also demonstrated good biocompati-
bility in vitro and in vivo. A longer accumulation of PSA-CC-
dye and FA-PSA-CC-dye micelles was observed in AIA mice
(Figure 5(A)). PSA-CC and FA-PSA-CC micelles also significantly
reduced Dex clearance from AIA rats and increased AUC of Dex
in AIA rats (Figure 5(B,C)). For the first time, PSA-based micelles
were shown to improve the pharmacokinetics of drugs in vivo.
In the period of inflammation, activated macrophages
show high expression of folate receptor-b (FRb) while quies-
cent resident macrophages have low or no expression of
folate receptor. FA possesses high affinity to FRb and has
been used as an efficient ligand for targeting to activated
macrophages (Rollett et al., 2012; Yang et al., 2014). Besides,
FA itself has been shown to inhibit LPS-induced inflammatory
response in RAW 264.7 macrophages by suppressing MAPKs
and NF-jB activation (Feng et al., 2011). Therefore, the
addition of FA to the micelles would facilitate FRb-mediated
cellular uptake by macrophages and FA induced suppression
of inflammation in macrophages.
Physical mixing is an easy method to prepared FA-
modified micelles. Mixing method avoid the introduction of
additional toxic chemicals from conjugation reaction and the
process of chemical residual removal. Instead of chemical con-
jugation of FA to PSA-CC, mixing of DSPE-PEG-FA with PSA-CC
formed a targeted micelle with smaller size, lower CMC, and
slower release of Dex, indicating that FA-PSA-CC micelles have
a higher stability and tighter structure than PSA-CC micelles.
FA was exposed to the surface of the mixed micelles. FA-PSA-
CC micelles showed more intracellular delivery of therapeutics
and could enhance the suppression of pro-inflammatory
proteins in vitro and in vivo. The evaluation of paw thickness,
clinical arthritis scores, and joint structure showed a better
anti-inflammatory arthritis efficacy of FA-PSA-CC micelles than
PSA-CC micelles. Therefore, the FA-PSA-CC mixed micelles pos-
sessed an easy preparation as well as high anti-
inflammatory efficacy.
High drug loading is essential to successful drug delivery.
Previous studies reported a Dex loading around 2% to PEG-
PCL micelles and PEG-PCL/PEG-PEI hybrid micelles (Wang
et al., 2016, 2017). The efficacy of Dex is dose-dependent.
Therefore, a higher loading of Dex to micelles can reduce the
amount of injected micelles into the body. By using an
improved Dex loading method, loading capacity of Dex was
increased to 10% in this study. The developed FA-PSA-CC/
Dex micelles also demonstrated a longer elimination half-life
and a higher AUC than previously reported Dex-loaded
micelles (Wang et al., 2016), indicating that FA-PSA-CC/Dex
micelles have more potential to be successfully transferred
into clinical use.
Conclusion
Compared to the discovery of new drugs, micellization of drugs
on market is an easier and more cost-effective strategy to
improve the efficacy and safety of treatments. This study
micellized a classical anti-inflammatory drug-Dex with the bio-
compatible PSA and CC for the treatment of rheumatoid arth-
ritis. Micellized Dex showed a proper size for passive targeting
to inflamed joints and high targeting to macrophages that
highly expressed FA receptor. Micellized Dex also demonstrated
good stability, effective suppression of key pro-inflammatory
proteins, improved PK of Dex, and good safety in vitro and
in vivo. These results indicate that the micellized Dex is a poten-
tial strategy to improve the treatment of rheumatoid arthritis in
clinical setting.
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